The Ofer-backed acromegaly treatment developer raised an initial $33.8m in January, following a cancelled deal with pharmaceutical company Roche.
Chiasma, an Israel-based biotechnology company backed by conglomerate Ofer Holdings, completed a $70m series E round on Friday following an initial tranche of $33.8m raised in January 2015.
The round was funded Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and Arch Venture Partners.
Ofer subsidiary Ofer Hi-Tech took part in a $44m series C round in 2006 that also featured Arch Venture Partners, MPM Capital and F2 Venture.
In total, Chiasma has secured about…
